The DOI matches its Crossref record.
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
Abstract
PURPOSE: To determine the efficacy and toxicity of topotecan administered as a 5-day intravenous infusion in patients with advanced ovarian cancer refractory to cisplatin-based chemotherapy. PATIENTS AND METHODS: Thirty patients with advanced epithelial ovarian cancer refractory to cisplatin-based chemotherapy received intravenous infusions of topotecan 1.5 mg/m2 delivered over 30 minutes each day for 5 days. A course was repeated every 21 days. The patient eligibility requirements included age > or = 18 years, Zubrod score < or = 2, measurable disease, adequate hepatic and renal function, neutrophil count > or = 1,500/microL, platelet count > or = 100,000/microL, and anticipated survival > or = 3 months. RESULTS: Twenty eight patients were assessable for response and toxicity. All patients were assessable for survival. The major toxicity from administration of topotecan at this dose schedule was myelosuppression; 21 patients required dose reductions. Four patients had neutropenic fever that required hospitalization, and seven patients required platelet transfusions. Maculopapular pruritic exanthema occurred in 20% of patients; gastrointestinal side effects were mild. No deaths were reported on the study. At dose levels of 1.5, 1.25, and 1.0 mg/m2, 61%, 31%, and 25% of patients, respectively, required dose reductions. Of 28 assessable patients, four (14%; 95% confidence interval [CI], 4% to 34%) achieved a partial response (PR) at a median of 1.4 months and lasting 8.9 months, and 17 had stable disease (SD). The overall median survival time was 10.0 months (95% CI, 8.1 to 13.5). CONCLUSION: Topotecan shows modest clinical activity against cisplatin-refractory ovarian cancer, although the dose-intensity is compromised by the depth of the granulocyte nadir and the duration of granulocytopenia. Further studies of topotecan may necessitate a reevaluation of optimal dose schedule, with the possible incorporation of multilineage cytokines, and its activity in taxane-resistant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
Groopman, J. E., & Itri, L. M. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.19.1616 · Cited by 929
Rose, P. G., Blessing, J. A., Mayer, A. R., & Homesley, H. D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.405 · Cited by 386
Bookman, M. A., Malmström, H., Bolis, G., Gordon, A., Lissoni, A., Krebs, J. B., & Fields, S. Z. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3345 · Cited by 321
Topoisomerase I inhibitors: Review and update
Rothenberg, M. L. (1997) · Annals of Oncology · doi:10.1023/a:1008270717294 · Cited by 306
Metadata
- Authors
- Kudelka, A. P., Tresukosol, D., Edwards, C. L., Freedman, R. S., Levenback, C., Chantarawiroj, P., Gonzalez de Leon, C., Kim, E. E., Madden, T., Wallin, B., Hord, M., Verschraegen, C., Raber, M., & Kavanagh, J. J.
- Venue
- Journal of Clinical Oncology
- Published
- 1996-05
- Volume
- 14
- Issue
- 5
- Pages
- 1552-1557
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1905580151
- Cited by
- 246
- References
- 0
- FWCI
- 17.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. https://app.cochat.ai/papers/10.1200/jco.1996.14.5.1552
- The paper
- Kudelka, A. P., Tresukosol, D., Edwards, C. L., Freedman, R. S., Levenback, C., Chantarawiroj, P., Gonzalez de Leon, C., Kim, E. E., Madden, T., Wallin, B., Hord, M., Verschraegen, C., Raber, M., & Kavanagh, J. J. (1996). Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1996.14.5.1552
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.